Natco Pharma Ltd

Stage 4 · Declining · week 11

As of 16 Oct 2026, Natco Pharma is in Stage 4 — declining, a downtrend, in week 11 (since 4 Aug 2026). It closed at ₹785, 34.9% below its 52-week high and below its 200-day average, which is falling. In Health Care, 40.6% of stocks are in Stage 2.

NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and int… More about the company

₹785.1
+0.01% today
₹14,445 Cr · Mid cap
Market Neutral — FadingHealth Care 40.6% in Stage 2-7.4 pts / 20dPharmaceuticals 50.4%-2.5 pts

Pro read

Pro

Our read

Declining — below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is NATCOPHARM early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-34.9%
₹782.7 lo₹1,206 hi
34.9% below 52W high — ongoing decline
In Stage 4, distance from the 52W high reflects ongoing decline — not a discount. Avoid catching falling knives.
Stage Maturity
Week 11
1w13w26w
Week 11 — established downtrend
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure — there's no 'bottom' time to buy.
vs 200 DMA
-16.0%
200 DMA: ₹934.7 · sloping down
In Stage 4, the stock is below its 200 DMA — the hallmark of a downtrend. No long positions warranted until this reverses structurally.
Rel Volume
1.08x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low volume bounces are typical — they lack real buyers and should not be mistaken for reversals.
Trend Health
↓
MA20 rolling over · -1.6% vs MA50 -5.8%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-3.5%
3M
-16.9%
6M
-27.8%
YTD
-14.9%
1Y
-2.6%
Sector
Health Care
↓ Peaking
Stage 2%
40.6%
20d Δ
-7.4pp
1M return
-3.8%
3M return
-1.0%
Sector Stage-2 % · last 20 days
Sector has 67 Stage 2 leaders. See Health Care Stage 2 →
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
50.4%
20d Δ
-2.5pp
1M return
-2.3%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Industry has 57 Stage 2 leaders. See Pharmaceuticals Stage 2 →
Stage Cycle Timeline2023-07-20 → 2026-10-16
S2 15w
S2 41w
S4 15w
S1 15w
S2 14w
2023-07-202026-10-16
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 15w → S3 11w → S2 41w → S3 9w → S2 2w → S3 4w → S4 15w → S1 15w → S4 13w → S1 4w → S2 6w → S3 1w → S4 2w → S3 1w → S2 14w → S3 7w → S4 11w current
Total tracked: 169 weeks across 17 stage runs.
Scan Membership
Breakout Watch
Latest: 2026-03-10
4 appearances in last 60 days. First seen: 2024-01-18.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding — staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-16S4
Wk 11 · Vol 1.08x
2026-10-15S4
Wk 11 · Vol 0.65x
2026-10-14S4
Wk 10 · Vol 1.02x
2026-10-13S4
Wk 10 · Vol 0.60x
2026-10-12S4
Wk 10 · Vol 1.11x
2026-10-09S4
Wk 10 · Vol 0.52x
2026-10-08S4
Wk 10 · Vol 0.70x
2026-10-07S4
Wk 9 · Vol 1.13x
2026-10-06S4
Wk 9 · Vol 0.51x
2026-10-05S4
Wk 9 · Vol 1.31x
2026-10-01S4
Wk 9 · Vol 1.66x
2026-09-30S4
Wk 9 · Vol 1.45x
Sector Peers — Stage 2All →
BAFNAPH
wk 19 · 0.0% from hi
8.6
KILITCH
wk 3 · -11.6% from hi
8.4
LAURUSLABS
wk 26 · -0.4% from hi
7.8
KOPRAN
wk 20 · -6.8% from hi
7.4
ZIMLAB
wk 23 · -5.2% from hi
6.9
Moving averages & range
50 DMA
₹844.4
200 DMA
₹934.7
52W High
₹1,206
52W Low
₹782.7
5D Low
₹782.7
Resistance levels (recent highs)
20d High
₹843.1
60d High
₹951.7
120d High
₹1,206
250d High
₹1,206
Next resistance
+7.4%
to 20d High
Ask the Market AI about NATCOPHARMAsk →
P/E (TTM)
13.5
Forward 29.4
Earnings Growth (YoY)
+13.9%
Revenue +36.3%
Dividend Yield
0.55%
P/B 2.4
About this companyHealth Care· Pharmaceuticals

NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-16. Past data patterns are not indicative of future results. This page is a data analytics tool only.